Study of the Antiviral Mechanism of Cytovir®-3 Against Respiratory Viruses In Vitro

Background. Modern clinical practice often excludes the possibility of differential diagnostics for acute respiratory viral infection pathogens and identification of a specific viral pathogen. In this regard, it is important to search for drugs with a broad spectrum of activity against pathogens of acute respiratory viral infections. The aim of the study was to assess the antiviral activity of the drug Cytovir®-3 in vitro against the cytopathogenic effect of human adenovirus. Material and methods. The antiviral effect of the drug Cytovir®-3 in comparison with the drug Umifenovir against human adenovirus type 5 was studied on Vero cell culture. The drugs were administered 1 hour before (prophylactic regimen) and 1 hour after (therapeutic regimen) infection of the cell culture with the virus. The working concentration range for the studied drugs was determined based on the 50% cytotoxic concentration values, calculated based on the results of the microtetrazolium (MTT) assay. Results and discussion . The drug Cytovir®-3 in two application regimens (therapeutic or prophylactic) demonstrated antiviral efficacy in vitro against human adenovirus in the non-toxic range (0-631 µg/ml) regardless of the application scheme (therapeutic or prophylactic ). Conclusion . The in vitro antiviral activity of the drug Cytovir®-3 against human adenovirus has been proven. Moreover, in all series of experiments, Cytovir®-3 had a selectivity index comparable to that of the reference drug Umifenovir.